Economic evaluation of the use of nadroparin in the treatment of deep- vein thrombosis in Switzerland

Annals of Pharmacotherapy

Volumn 31, Issue 7-8, 1997, Pages 842-846

  Lloyd, Adam C ^a,b   Aitken, Judith A ^a   Hoffmeyer, Ullrich K ^b,c   Kelso, Emma J ^a,c   Wakerly, Elizabeth C ^c   Barber, Nicholas D ^d  

^a NERA ECONOMIC CONSULTING   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Natl Economic Research Associates   (United Kingdom)

^d UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Deep vein thrombosis; Nadroparin; Unfractioned heparin

Indexed keywords

NADROPARIN;

ANTICOAGULATION; ARTICLE; CLINICAL PRACTICE; COST CONTROL; DEEP VEIN THROMBOSIS; HEALTH ECONOMICS; HUMAN; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; SWITZERLAND;

EID: 0030769316     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703100705     Document Type: Article

References (19)

1. Hull RD, Pineo G. Low-molecular-weight heparins for the treatment of venous thromboembolism. Ann Med 1993;25:457-62.
2. Hull RD, Raskob GE, Hirsh J, Yay RM, Leclerc JR, Geerts WH, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986;315:1109-14.
3. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975-82.
4. Lopaciuk S, Meissner AJ, Filipecki S, Zawilska K, Sowier J, Ciesielski L, et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thromb Haemostas 1992;68:14-8.
5. Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. BMJ 1994;309:299-304.
6. Hommes DW, Bura A, Mazzolai L, Büller HR, ten Cate JW. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. Ann Intern Med 1992;116:279-84.
7. Gallus AS. Overview of the management of thrombotic disorders. Semin Thromb Haemostas 1989;15:99-110.
8. Kelton JG, Hirsh J. Bleeding associated with antithrombotic therapy. Semin Hematol 1980;17:259-95.
9. Pineo GF, Hull RD. Prevention and treatment of venous thromboembolism. Drugs 1996;52:71-92.
10. Colvin BT, Barrowcliffe TW. The British Society for Haematology guidelines on the use and monitoring of heparin 1992, 2nd Revision. J Clin Pathol 1993;46:97-103.
11. Frydman AM, Bara L, Le Roux Y, Woler M, Chauliac F, Samama MM. The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol 1988;28:609-18.
12. Ninet J, Bachet P, Prandoni P, Ruol A, Vigo M, Barret A, et al. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study. Thromb Haemostas 1991;65:251-6.
13. Prandoni P, Lensing AWA, Büller HR, Carter M, Cogo A, Vigo M, et al. Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximal deep vein thrombosis. Lancet 1992; 339:441-5.
14. South West Thames Regional Drug Information Centre, New Product Assessment. Low-molecular-weight heparins. Mimeograph of the Drug Information Pharmacists' Group, March 1991.
15. Thery C, Simonneau G, Meyer G, Helenon O, Bridey F, Armagnac C, et al. Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study. Circulation 1992;85:1380-9.
16. Yorkshire Regional Drug Information Services. Low-molecular-weight heparins. Yorkshire Reg Drug Info Update 1992;2:1-4.
17. Teo CP, Lim HL, Kuch YK. Cost effectiveness and ease of administration of low-molecular-weight heparin in deep vein thrombosis. Thromb Haemostas 1994;72:328-9.
18. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-81.
19. Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-7.